Compare BLNK & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLNK | MGTX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.2M | 1.0B |
| IPO Year | 2008 | 2018 |
| Metric | BLNK | MGTX |
|---|---|---|
| Price | $0.56 | $10.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $2.33 | ★ $24.57 |
| AVG Volume (30 Days) | ★ 992.3K | 845.6K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.22 | 33.02 |
| EPS | N/A | ★ 1.30 |
| Revenue | ★ $126,197,000.00 | $81,391,000.00 |
| Revenue This Year | $5.71 | $141.38 |
| Revenue Next Year | $19.65 | N/A |
| P/E Ratio | ★ N/A | $8.55 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $0.45 | $6.62 |
| 52 Week High | $2.65 | $15.35 |
| Indicator | BLNK | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 28.36 |
| Support Level | $0.52 | $8.84 |
| Resistance Level | $0.62 | $11.85 |
| Average True Range (ATR) | 0.02 | 0.56 |
| MACD | 0.00 | -0.26 |
| Stochastic Oscillator | 42.12 | 11.28 |
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The Blink's principal line of products and services is its Blink EV charging networks, Blink EV charging equipment, and other EV-related services. The Blink Network is a proprietary, cloud-based system that operates, maintains, and manages Blink charging stations and handles the associated charging data, back-end operations, and payment processing. The Blink Network provides fleets, property owners, managers, parking companies, and state and municipal entities, among other types of commercial customers, with cloud-based services.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.